Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03632915 · ClinicalTrials.gov registry record

Pharmacokinetics of Antiepileptics in Patients on CRRT

A clinical trial of Acute Kidney Injury and Pharmacokinetics, sponsored by University of Maryland, Baltimore.

Completed
Registry status
18
Enrollment target
1
Study location

NCT03632915 is a study of Acute Kidney Injury and Pharmacokinetics that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 18 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03632915, a study of Acute Kidney Injury and Pharmacokinetics, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to measure levels of any of the following AEDs (levetiracetam, phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and optimize dosing strategies in patients on CRRT.

Interventions

  • DRUG Ketamine
  • DRUG Levetiracetam
  • DRUG Lacosamide
  • DRUG Phenytoin
  • DRUG Phenobarbital

Study Locations (1)

Maryland

  • University of Maryland Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2017-11-20
Est. Completion 2019-12-31

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT03632915

The ClinicalTrials.gov registry entry for NCT03632915 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 5 interventions - of which Ketamine is the first listed.

NCT03632915 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03632915 about?

NCT03632915 is a clinical study titled "Pharmacokinetics of Antiepileptics in Patients on CRRT". The purpose of the study is to measure levels of any of the following AEDs (levetiracetam, phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and optimize dosing strategies in p...

What is the current status of trial NCT03632915?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2017-11-20. Estimated completion is 2019-12-31.

What conditions does trial NCT03632915 study?

This clinical trial studies the following conditions: Acute Kidney Injury, Pharmacokinetics, Renal Insufficiency, Renal Failure.

What interventions are being tested in trial NCT03632915?

The interventions under investigation include: Ketamine (DRUG), Levetiracetam (DRUG), Lacosamide (DRUG), Phenytoin (DRUG), Phenobarbital (DRUG).

Who is sponsoring clinical trial NCT03632915?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03632915 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Kidney Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.